Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 10, 2003, Pages 2149-2156

  Zarranz, Belén ^a   Jaso, Andrés ^a   Aldana, Ignacio ^a   Monge, Antonio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL N (2 METHYLPHENYL)QUINOXALINE 2 CARBOXAMIDE 1,4 DIOXIDE; 3 METHYL N PHENYLQUINOXALINE 2 CARBOXAMIDE 1,4 DIOXIDE; 7 CHLORO 3 METHYL N (2 METHYLPHENYL)QUINOXALINE 2 CARBOXAMIDE 1,4 DIOXIDE; AMIDE; AROMATIC COMPOUND; CHEMICAL COMPOUND; METHYL GROUP; OXIDE; QUINOXALINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL LINE; DRUG EFFECT; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; INFRARED RADIATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOMETRY; SCREENING; THIN LAYER CHROMATOGRAPHY; VERO CELL;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0037447952     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00119-6     Document Type: Article

References (16)

1. Savini L., Chiasserini L., Gaeta A., Pellerano C. Bioorg. Med. Chem. 10:2002;2193.
2. Pathak R., Pant C.S., Shaw A.K., Bhaduri A.P., Gaikwad A.N., Sinha S., Srivastava A., Srivastava K.K., Chaturvedi V., Srivastava R., Srivastava B.S. Bioorg. Med. Chem. 10:2002;3187.
3. Bass J.B. Jr., Farer L.S., Hopewell P.C., O'Brien R., Jacobs R.F., Ruben F., Snider D.E.Jr., Thornton G. The American Thoracic Society. Am. J. Respir. Crit. Care Med. 149:1994;1359.
4. Pathak A.K., Pathak V., Seitz L., Maddry J.A., Gurcha S.S., Besra G.S., Suling W.J., Reynolds R.C. Bioorg. Med. Chem. 9:2001;3129.
5. Ortega M.A., Montoya M.E., Jaso A., Zarranz B., Tirapu I., Aldana I., Monge A. Die Pharmazie. 56:2001;205.
6. Ortega M.A., Sainz Y., Montoya M.E., Jaso A., Zarranz B., Aldana I., Monge A. Arzneim. Forsch./Drug Res. 52:2002;113.
7. Ortega M.A., Sainz Y., Montoya M.E., López de Ceráin A., Monge A. Die Pharmazie. 54:1999;24.
8. Sainz Y., Montoya M.E., Martínez-Crespo F.J., Ortega M.A., López de Ceráin A., Monge A. Arzneim. -Forsch. Drug Res. 49:1999;55.
9. Montoya M.E., Sainz Y., Ortega M.A., López de Ceráin A., Monge A. Organización Farmacéutica Ibero-Latinoamericana (O.F.I.L.). 8:1998;36.
10. Montoya M.E., Sainz Y., Ortega M.A., López de Ceráin A., Monge A. Il Farmaco. 53:1998;570.
11. Openshaw H.T., Whittaker N. J. Med. Soc. 89:1968.
12. Cheeseman, G. W. H.; Cookson, R. F. In Condensed Pyrazines, J. Wiley and Sons: New York, 1979; p 35.
13. Ortega M.A., Morancho M.J., Martínez-Crespo F.J., Sainz Y., Montoya M.E., Cerain A.L., Monge A. Eur. J. Med. Chem. 35:2000;21.
14. Collins L., Franzblau S.G.Antimicrob. Agents Chemother. 41:1997;1004.
15. Skinner P.S., Furney S.K., Jacobs M.R., Klopman G., Ellner J.J., Orme I.M. Antimicrob. Agents Chemother. 38:1994;2557.
16. Franzblau S.G., Witzig R.S., McLaughlin J.C., Torres P., Madico G., Hernandez A., Degnan M.T., Cook M.B., Quenzer V.K., Freguson R.M., Gilman R.H. J. Clin. Microb. 36:1998;362.